PDL On Other Exchanges
Natl India

parabolic drugs ltd (PDL) Snapshot

Previous Close
Day High
Day Low
52 Week High
-- - --
52 Week Low
-- - --
Market Cap
Average Volume 10 Days
Shares Outstanding
Dividend Yield
Current Stock Chart for PARABOLIC DRUGS LTD (PDL)

Related News

No related news articles were found.

parabolic drugs ltd (PDL) Related Businessweek News

No Related Businessweek News Found

parabolic drugs ltd (PDL) Details

Parabolic Drugs Limited develops, manufactures, and sells active pharmaceutical ingredients (API) and API intermediates in India. The company offers oral and sterile semi synthetic penicillin APIs; oral and sterile cephalosporin APIs in antibiotic area; non-antibiotic APIs for cardiovascular, NSAID, anti-hypertensive, and osteoporosis therapeutic areas; and calcium sennoside, colchicine, raubasine, reserpine, thiocolchicoside, vinpocetine, and yohimbine. It also provides custom research and manufacturing services to pharma companies, including research and development, and manufacturing services for NCE and generics; IPR support for process design and infringement guidance; and QA, QC, and regulatory support for meeting quality and documentation requirements. The company also exports its products to approximately 51 countries. Parabolic Drugs Limited was founded in 1996 and is based in Chandigarh, India.

1,011 Employees
Last Reported Date: 07/20/10
Founded in 1996

parabolic drugs ltd (PDL) Top Compensated Officers

Chairman, MD & Compliance Officer
Total Annual Compensation: --
Whole- Time Director
Total Annual Compensation: --
Compensation as of Fiscal Year 2018.
parabolic drugs ltd
Parabolic Drugs Limited to Report Fiscal Year 2019 Results on May 29, 2019

Parabolic Drugs Limited announced that they will report fiscal year 2019 results on May 29, 2019

Parabolic Drugs Limited, Board Meeting, May 29, 2019

Parabolic Drugs Limited, Board Meeting, May 29, 2019. Agenda: To consider and approve the audited financial results of the company for the financial year ended on March 31, 2019.

Parabolic Drugs Limited Reports Unaudited Earnings Results for the Quarter Ended September 30, 2018

Parabolic Drugs Limited reported unaudited earnings results for the quarter ended September 30, 2018. For the quarter, the company reported total revenue from operations of INR 49.7 million against INR 239.6 million a year ago. Total income was INR 56.3 million against INR 243.0 million a year ago. Net loss after tax from continuing operations was INR 143.4 million against INR 142.3 million a year ago. Total comprehensive loss was INR 143.4 million against INR 142.3 million a year ago. Basic loss per share was INR 2.32 against INR 2.30 a year ago.


The information and data displayed in this profile are created and managed by S&P Global Market Intelligence, a division of S&P Global. Bloomberg.com does not create or control the content. For inquiries, please contact S&P Global Market Intelligence directly by clicking here.

Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup

PDL Competitors

Market data is delayed at least 15 minutes.

Company Last Change
No competitor information is available for PDL.
View Industry Companies

Industry Analysis


Industry Average

Valuation PDL Industry Range
Price/Earnings NM Not Meaningful
Price/Sales -- Not Meaningful
Price/Book -- Not Meaningful
Price/Cash Flow NM Not Meaningful
TEV/Sales -- Not Meaningful

Sponsored Financial Commentaries

Sponsored Links

Request Profile Update

Only a company representative may request an update for the company profile. Documentation will be required.

To contact PARABOLIC DRUGS LTD, please visit www.parabolicdrugs.com. Company data is provided by S&P Global Market Intelligence. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at bwwebmaster@businessweek.com.